vs

Side-by-side financial comparison of Axon Enterprise (AXON) and Cooper Companies (The) (COO). Click either name above to swap in a different company.

Cooper Companies (The) is the larger business by last-quarter revenue ($1.1B vs $796.7M, roughly 1.3× Axon Enterprise). Cooper Companies (The) runs the higher net margin — 7.9% vs 0.3%, a 7.6% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs 4.6%). Axon Enterprise produced more free cash flow last quarter ($155.4M vs $149.9M). Over the past eight quarters, Axon Enterprise's revenue compounded faster (31.5% CAGR vs 6.9%).

Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.

AXON vs COO — Head-to-Head

Bigger by revenue
COO
COO
1.3× larger
COO
$1.1B
$796.7M
AXON
Growing faster (revenue YoY)
AXON
AXON
+34.4% gap
AXON
38.9%
4.6%
COO
Higher net margin
COO
COO
7.6% more per $
COO
7.9%
0.3%
AXON
More free cash flow
AXON
AXON
$5.5M more FCF
AXON
$155.4M
$149.9M
COO
Faster 2-yr revenue CAGR
AXON
AXON
Annualised
AXON
31.5%
6.9%
COO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXON
AXON
COO
COO
Revenue
$796.7M
$1.1B
Net Profit
$2.7M
$84.6M
Gross Margin
57.9%
61.1%
Operating Margin
-6.3%
13.2%
Net Margin
0.3%
7.9%
Revenue YoY
38.9%
4.6%
Net Profit YoY
-98.0%
-28.0%
EPS (diluted)
$0.02
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXON
AXON
COO
COO
Q4 25
$796.7M
$1.1B
Q3 25
$710.6M
$1.1B
Q2 25
$668.5M
$1.0B
Q1 25
$603.6M
$964.7M
Q4 24
$573.4M
$1.0B
Q3 24
$544.3M
$1.0B
Q2 24
$504.1M
$942.6M
Q1 24
$460.7M
$931.6M
Net Profit
AXON
AXON
COO
COO
Q4 25
$2.7M
$84.6M
Q3 25
$-2.2M
$98.3M
Q2 25
$36.1M
$87.7M
Q1 25
$88.0M
$104.3M
Q4 24
$136.0M
$117.5M
Q3 24
$67.0M
$104.7M
Q2 24
$40.8M
$88.9M
Q1 24
$133.2M
$81.2M
Gross Margin
AXON
AXON
COO
COO
Q4 25
57.9%
61.1%
Q3 25
60.1%
65.3%
Q2 25
60.4%
67.8%
Q1 25
60.6%
68.4%
Q4 24
60.5%
66.5%
Q3 24
60.8%
66.1%
Q2 24
60.3%
67.0%
Q1 24
56.4%
67.0%
Operating Margin
AXON
AXON
COO
COO
Q4 25
-6.3%
13.2%
Q3 25
-0.3%
16.6%
Q2 25
-0.2%
18.4%
Q1 25
-1.5%
18.9%
Q4 24
-2.6%
19.5%
Q3 24
4.4%
19.2%
Q2 24
6.5%
17.2%
Q1 24
3.5%
16.4%
Net Margin
AXON
AXON
COO
COO
Q4 25
0.3%
7.9%
Q3 25
-0.3%
9.3%
Q2 25
5.4%
8.7%
Q1 25
14.6%
10.8%
Q4 24
23.7%
11.5%
Q3 24
12.3%
10.4%
Q2 24
8.1%
9.4%
Q1 24
28.9%
8.7%
EPS (diluted)
AXON
AXON
COO
COO
Q4 25
$0.02
$0.42
Q3 25
$-0.03
$0.49
Q2 25
$0.44
$0.44
Q1 25
$1.08
$0.52
Q4 24
$1.68
$0.59
Q3 24
$0.86
$0.52
Q2 24
$0.53
$0.44
Q1 24
$1.73
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXON
AXON
COO
COO
Cash + ST InvestmentsLiquidity on hand
$1.7B
$110.6M
Total DebtLower is stronger
$1.8B
$2.5B
Stockholders' EquityBook value
$3.2B
$8.2B
Total Assets
$7.0B
$12.4B
Debt / EquityLower = less leverage
0.56×
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXON
AXON
COO
COO
Q4 25
$1.7B
$110.6M
Q3 25
$2.4B
$124.9M
Q2 25
$2.1B
$116.2M
Q1 25
$2.2B
$100.9M
Q4 24
$788.1M
$107.6M
Q3 24
$1.0B
$109.7M
Q2 24
$968.9M
$112.4M
Q1 24
$964.1M
$135.2M
Total Debt
AXON
AXON
COO
COO
Q4 25
$1.8B
$2.5B
Q3 25
$2.0B
$2.4B
Q2 25
$2.0B
$2.5B
Q1 25
$2.0B
$2.5B
Q4 24
$680.3M
$2.6B
Q3 24
$2.6B
Q2 24
$2.7B
Q1 24
$2.7B
Stockholders' Equity
AXON
AXON
COO
COO
Q4 25
$3.2B
$8.2B
Q3 25
$3.0B
$8.4B
Q2 25
$2.7B
$8.3B
Q1 25
$2.6B
$8.1B
Q4 24
$2.3B
$8.1B
Q3 24
$2.1B
$7.9B
Q2 24
$1.9B
$7.8B
Q1 24
$1.8B
$7.7B
Total Assets
AXON
AXON
COO
COO
Q4 25
$7.0B
$12.4B
Q3 25
$6.7B
$12.4B
Q2 25
$6.2B
$12.4B
Q1 25
$6.1B
$12.2B
Q4 24
$4.5B
$12.3B
Q3 24
$4.0B
$12.1B
Q2 24
$3.7B
$12.0B
Q1 24
$3.6B
$12.0B
Debt / Equity
AXON
AXON
COO
COO
Q4 25
0.56×
0.30×
Q3 25
0.66×
0.29×
Q2 25
0.73×
0.30×
Q1 25
0.79×
0.31×
Q4 24
0.29×
0.32×
Q3 24
0.33×
Q2 24
0.34×
Q1 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXON
AXON
COO
COO
Operating Cash FlowLast quarter
$217.2M
$247.9M
Free Cash FlowOCF − Capex
$155.4M
$149.9M
FCF MarginFCF / Revenue
19.5%
14.1%
Capex IntensityCapex / Revenue
7.8%
9.2%
Cash ConversionOCF / Net Profit
79.14×
2.93×
TTM Free Cash FlowTrailing 4 quarters
$75.1M
$433.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXON
AXON
COO
COO
Q4 25
$217.2M
$247.9M
Q3 25
$60.0M
$261.4M
Q2 25
$-91.7M
$96.2M
Q1 25
$25.8M
$190.6M
Q4 24
$250.2M
$268.1M
Q3 24
$91.3M
$207.5M
Q2 24
$82.8M
$111.0M
Q1 24
$-15.9M
$122.7M
Free Cash Flow
AXON
AXON
COO
COO
Q4 25
$155.4M
$149.9M
Q3 25
$33.4M
$164.5M
Q2 25
$-114.7M
$18.1M
Q1 25
$932.0K
$101.2M
Q4 24
$225.4M
$128.1M
Q3 24
$64.8M
$118.5M
Q2 24
$71.4M
$36.9M
Q1 24
$-32.1M
$4.6M
FCF Margin
AXON
AXON
COO
COO
Q4 25
19.5%
14.1%
Q3 25
4.7%
15.5%
Q2 25
-17.2%
1.8%
Q1 25
0.2%
10.5%
Q4 24
39.3%
12.6%
Q3 24
11.9%
11.8%
Q2 24
14.2%
3.9%
Q1 24
-7.0%
0.5%
Capex Intensity
AXON
AXON
COO
COO
Q4 25
7.8%
9.2%
Q3 25
3.7%
9.1%
Q2 25
3.4%
7.8%
Q1 25
4.1%
9.3%
Q4 24
4.3%
13.7%
Q3 24
4.9%
8.9%
Q2 24
2.2%
7.9%
Q1 24
3.5%
12.7%
Cash Conversion
AXON
AXON
COO
COO
Q4 25
79.14×
2.93×
Q3 25
2.66×
Q2 25
-2.54×
1.10×
Q1 25
0.29×
1.83×
Q4 24
1.84×
2.28×
Q3 24
1.36×
1.98×
Q2 24
2.03×
1.25×
Q1 24
-0.12×
1.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXON
AXON

Software And Sensors Segment$342.5M43%
TASER Devices Professional$264.2M33%
Personal Sensors$109.1M14%
Platform Solutions$80.9M10%

COO
COO

Sphere Other$365.0M34%
Toric And Multifocal$344.7M32%
Office And Surgical$214.5M20%
Fertility$140.9M13%

Related Comparisons